Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
Pliant Therapeutics, Inc.
Eli Lilly and Company
Novartis
Hutchmed
Arbele Limited
Imugene Limited
Myeloid Therapeutics
Servier
Seagen Inc.
Incyte Corporation
Actym Therapeutics, Inc.
MacroGenics
Elicio Therapeutics
Eli Lilly and Company
Leap Therapeutics, Inc.
Toray Industries, Inc
NextPoint Therapeutics, Inc.
Eli Lilly and Company
Celldex Therapeutics
Kinnate Biopharma
Toray Industries, Inc
Boehringer Ingelheim
Zymeworks BC Inc.
Symphogen A/S
ABM Therapeutics Shanghai Company Limited
NGM Biopharmaceuticals, Inc
Tyra Biosciences, Inc
Symphogen A/S
ABM Therapeutics Corporation
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Sirnaomics
Wellmarker Bio
Celon Pharma SA
MacroGenics
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Hutchmed
Tempest Therapeutics
Celldex Therapeutics
Xencor, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
Wellmarker Bio
Bayer
AbbVie
AbbVie